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microRNAs (miRNAs) are widespread regulators of gene expression, but little is known of
their potential roles in congenital muscular dystrophy type 1A (MDC1A). MDC1A is a severe
form of muscular dystrophy caused by mutations in the gene encoding laminin α2 chain.To
gain insight into the pathophysiological roles of miRNAs associated with MDC1A pathology,
laminin α2 chain-deficient mice were evaluated by quantitative PCR. We demonstrate that
expression of muscle-specific miR-1, miR-133a, and miR-206 is deregulated in laminin α2
chain-deficient muscle. Furthermore, expression of miR-223 and miR-21, associated with
immune cell infiltration and fibrosis, respectively, is altered. Finally, we show that plasma
levels of muscle-specific miRNAs are markedly elevated in laminin α2 chain-deficient mice
and partially normalized in response to proteasome inhibition therapy. Altogether, our data
suggest important roles for miRNAs in MDC1A pathology and we propose plasma levels
of muscle-specific miRNAs as promising biomarkers for the progression of MDC1A.
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INTRODUCTION
Muscular dystrophy encompasses a group of inherited disorders
mainly affecting skeletal muscle. Different types of muscular dys-
trophy are genetically diverse but share common phenotypic fea-
tures including progressive myofiber degeneration, muscle weak-
ness, and declined muscle function (Cohn and Campbell, 2000).
Mutations in the human LAMA2 gene, encoding the laminin α2
chain, lead to congenital muscular dystrophy type 1A (MDC1A).
MDC1A is a severe form of muscular dystrophy characterized
by hypotonia at birth, muscle weakness, delayed motor develop-
ment, and joint contractures (Tome et al., 1994). Laminins are
cruciform or T-shaped heterotrimeric molecules composed of
one α, one β, and one γ subunit. To date, at least 18 different
laminin isoforms have been identified. However, the most abun-
dant laminin isoform in the skeletal muscle basement membrane
is laminin-211 (α2, β1, and γ1) (Ehrig et al., 1990). Together with
the dystrophin–glycoprotein complex laminin-211 forms a link
between the basement membrane and the intracellular cytoskele-
ton protecting the muscle fiber from contraction-induced damage
(Ervasti and Campbell, 1993).
Despite considerable research efforts there is currently no
cure for MDC1A. Hence, the discovery that microRNAs (miR-
NAs) are deregulated in muscle diseases makes them attractive
therapeutic targets (Eisenberg et al., 2007). miRNAs are small
non-protein-coding RNAs, which regulate gene expression at the
post-transcriptional level (Chen and Rajewsky, 2007). Investiga-
tions of miRNA expression and function in dystrophic muscles
have identified a large number of deregulated miRNAs. Among
the best characterized are three muscle-specific miRNAs: miR-1,
miR-133a, and miR-206 (Chen et al., 2006; Yuasa et al., 2008).
Moreover, miRNAs associated with specific features of muscular
dystrophy such as infiltration of inflammatory cells (miR-223) and
fibrogenesis (miR-21 and miR-29), are also altered in dystrophic
muscles (Eisenberg et al., 2007; Greco et al., 2009). In addition,
miRNAs are released into the blood stream of muscular dystro-
phy patients and mouse models, indicating that they represent
biomarkers for disease progression and experimental therapies
(Cacchiarelli et al., 2011; Mizuno et al., 2011).
An extended analysis of miRNA expression in MDC1A patients
or mouse models has never been performed. Hence, in this
study, we have analyzed expression of six miRNAs (miR-1, miR-
133a, miR-206, miR-21, miR-29c, and miR-223) in muscle and
plasma from two different MDC1A mouse models (dy3K/dy3K
and dy2J/dy2J). The dy3K/dy3K mouse is completely deficient for
laminin α2 and displays very severe muscle pathology whereas
the dy2J/dy2J mouse, which expresses reduced levels of a truncated
laminin α2, displays a milder muscular phenotype. Together, these
mouse models are representative of the complexity of the MDC1A
pathology.
Finally, our research group recently observed increased protea-
somal activity in skeletal muscle from dy3K/dy3K mice, an obser-
vation that seems to be specific for muscular dystrophy caused
by loss of laminin-211. Here, we have taken advantage of a pro-
teasome inhibitor that reduces the dy3K/dy3K pathology (Körner
et al., 2014), to investigate whether reduction in muscle pathology
correlates with levels of muscle-specific miRNAs in plasma.
MATERIALS AND METHODS
ANIMAL MODELS
Laminin α2 chain-deficient dy3K/dy3K mice have been described
(Miyagoe et al., 1997). Wild-type and dy2J/dy2J (B6.WK-
Lama2dy-2J/J) (Xu et al., 1994; Sunada et al., 1995) were purchased
from Jackson laboratory and bred in the Biomedical Center vivar-
ium in accordance with the animal care guidelines set by the
Malmö/Lund (Sweden) ethical committee for animal research.
Mice were analyzed at 6 weeks of age (dy2J/dy2J), 3 weeks of age
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(dy3K/dy3K),or at 9 days of age (young dy3K/dy3K). All comparisons
were made against age-matched wild-type mice.
RNA ISOLATION
Skeletal muscle total RNA was extracted from quadriceps muscles
snap-frozen in liquid nitrogen using the miRCURY RNA Isolation
Kit following the manufacturer’s instructions (Exiqon). Blood was
collected from heart puncture and transferred to anticoagulant
tubes (EDTA) and centrifuged at 1100× g for 10 min. Total RNA
from blood plasma was extracted following the manufacturer’s
instructions (Qiagen miRNeasy® Mini Kit). Briefly, plasma was
thawed on ice and centrifuged at 3000× g for 5 min in a 4°C cen-
trifuge. Fifty microliters of plasma per sample was transferred to a
new microcentrifuge tube and 190µl of QIAzol mixture contain-
ing 0.8µg/µl MS2 bacteriophage RNA (Roche Applied Science)
was added to each tube. Fifty microliters of chloroform was added
to each tube followed by centrifugation at 12000× g for 15 min
in a 4°C microcentrifuge. The supernatant was transferred to a
new microcentrifuge tube and 435µl ethanol was added to each
sample. A rinse step was performed with 1× 500µl RWT buffer
and 3× 500µl RPE buffer. Total RNA was eluted by adding 50µl
RNase-free water to the membrane of the Qiagen RNeasy Mini
spin column followed by centrifugation at 15000× g for 1 min.
The RNA was stored at−80°C.
QUANTITATIVE RT-PCR
Twenty nanograms of muscle RNA was reverse transcribed using
the miRCURY LNA Universal RT cDNA Synthesis Kit (Exiqon).
The cDNA was diluted 80× and assayed in 10µl PCR reactions
according to the protocol for the miRCURY LNA Universal RT
miRNA PCR system. The amplification was performed in a Light-
Cycler 480 Real-Time PCR System (Roche) in 96-well plates.
Primers were designed by Exiqon. Delta–delta Ct values were
calculated relative to let-7a and miR-16 (Roberts et al., 2012).
One microliter of RNA blood plasma eluate was reverse tran-
scribed in a 10µl reaction using the miRCURY LNA Universal RT
cDNA Synthesis Kit (Exiqon). The cDNA was diluted 40× and
assayed in a 10µl reaction according to the protocol for the miR-
CURY LNA™ Universal RT miRNA PCR system (Exiqon). miRNA
plasma levels were calculated relative to miR-21a and miR-223
(Roberts et al., 2012).
No-RT control reactions were performed to ensure no DNA
carryover. All amplifications were performed in triplicate on a
LightCycler 480 Real-Time PCR System (Roche) in 96-well plates.
The amplification curves were analyzed using the Roche LC soft-
ware for determination of Cp (by second derivate method) and for
melting curve analysis. The miRCURY RNA spike-in kit (synthetic
control template) was used to control for the quality of the cDNA
synthesis reaction. All oligonucleotide sequences were designed
by and ordered from Exiqon with the following product num-
bers: hsa-miR-1, 204344; hsa-let-7a-5p, 204775; hsa-miR-16-5p,
204409; hsa-miR-21-5p, 204230; hsa-miR-29c-3p, 204729; hsa-
miR-133a, 204788; hsa-miR-206, 204616; and hsa-miR-223-3p,
204256.
HISTOLOGY
Quadriceps muscles were isolated and frozen in OCT (Tissue
Tek) in liquid nitrogen. Transverse cryosections of 8µm were
transferred to positively charged glass slides and stored in−80°C.
Sections were stained with hematoxylin and eosin (H&E) for quan-
tification of centrally nucleated fibers or with Sirius red and Fast
green (Sigma-Aldrich) for visualization of collagenous and non-
collagenous tissue, respectively. Central nucleation is represented
as a percentage of the total number of fibers counted in entire
transverse quadriceps sections. For Sirius red and Fast green stain-
ing, sections were acclimated to RT for 15 min and fixated in
Bouin’s solution at 55°C for 1 h, incubated in 0.1% Fast green
for 10 min followed by incubation in 0.1% Picro Sirius red for
30 min. Sections were then dehydrated in ethanol and cleared in
xylene.
IMMUNOFLUORESCENCE ASSAYS
Transverse sections of 8µm were fixed in ice-cold acetone for
8 min. For CD11b (rat monoclonal M1/70, 1:300, BD Pharmin-
gen), CD68 (rat monoclonal FA-11, 1:100, AbD Serotec), and
laminin γ1 chain (rabbit polyclonal 1083+ E1, 1:100, kindly pro-
vided by Dr. T. Sasaki), sections were blocked in 3% BSA in PBS
at RT for 30 min followed by incubation in primary antibody at
RT for 1 h. For embryonic myosin heavy chain (mouse mon-
oclonal F1.652, 1:10, Developmental Studies Hybridoma Bank),
sections were blocked in 4% goat serum and 0.05% Triton-X in
PBS at RT for 40 min followed by incubation in primary anti-
body at RT for 90 min. Primary antibodies were incubated with
appropriate secondary antibodies for 60 or 45 min (embryonic
myosin heavy chain). Antibody stained sections were analyzed
using a Zeiss Axioplan fluorescent microscope using Openlab 3
and an ORCA 1394 ER digital camera. The percentage of embry-
onic myosin heavy chain–positive fibers was obtained by counting
the number of fibers positive for embryonic myosin heavy chain
in a whole quadriceps section and dividing by the total number of
myofibers.
HYDROXYPROLINE ASSAY (COLLAGEN CONTENT IN MUSCLE)
Quadriceps muscles were isolated and frozen in liquid nitro-
gen. Samples were weighed and incubated overnight in 200µl
concentrated HCl (12 M) at 95°C. Twenty five microliters of
hydrolyzate was neutralized with 25µl NaOH (0.6 M) and incu-
bated with 450µl Chloramine-T reagent (0.056 M) at RT for
25 min. A volume of 500µl freshly prepared Ehrlich’s reagent
[1 M 4-(dimethylamino)benzaldehyde] was added to each sam-
ple and incubated at 65°C for 1 h. After cooling on ice, 100µl in
duplicates was transferred to a 96-well plate and absorbance was
read at 560 nm. Standards from 4-hydroxyproline at concentra-
tions (microgram per milliliter); 0, 0.05, 0.1, 0.15, 0.2, 0.25, 0.4
were treated the same way as the samples. Absorbance (A560) of
standards was plotted against amount of hydroxyproline (micro-
gram) and a linear regression was performed to determine slope
and intercept. All absorbance values were subtracted with blank
(0µg/ml hydroxyproline). Content of hydroxyproline in samples
was calculated by equation:
x
(
µg
) = (A560 − Yaxis intercept) /slope
Collagen conversion factor= 13.5 (Neuman and Logan, 1950).
Values are presented as relative amount of collagen.
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CREATINE KINASE ASSAY
Blood was collected from heart puncture and transferred to anti-
coagulant tubes (EDTA) and centrifuged at 1100× g for 10 min
at 4°C. Plasma was analyzed at Clinical Chemistry Laboratory at
Skåne University Hospital. The CK_P_S Cobas method was used
to quantify enzyme activity.
BORTEZOMIB TREATMENT
Briefly, dy3K/dy3K mice were administered 0.4 mg/kg bortezomib
(LC Laboratories) via tail vein injection at 2.5 and 3.5 weeks of age.
Mice were analyzed 14 days after injection (Körner et al., 2014).
STATISTICAL ANALYSES
Data shown in qRT-PCR analyses are the result of at least three
independent experiments. Statistical significance of differences
between means was assessed by one-way analysis of variance.
Multiple comparisons were performed using the Holm–Sidak
method. Unpaired t -test was used when two groups were com-
pared. P < 0.05 was considered significant. All statistical analysis
was performed using PRISM 6.0b software (GraphPad).
RESULTS
ALTERED EXPRESSION OF MUSCLE-SPECIFIC miRNAs IN dy 3K /dy 3K
AND dy 2J /dy 2J QUADRICEPS MUSCLE
To determine whether miRNAs previously shown to be differen-
tially expressed in dystrophic muscle (Eisenberg et al., 2007; Greco
et al., 2009) are deregulated in MDC1A, we investigated miRNA
expression in two different mouse models: dy3K/dy3K (completely
devoid of lamininα2 chain) and dy2J/dy2J mice (expressing slightly
reduced levels of a truncated laminin α2 chain) (Xu et al., 1994;
Miyagoe et al., 1997). The dy3K/dy3K mice were analyzed at 3 weeks
of age due to lethality between 4 and 5 weeks of age. The dy2J/dy2J
mice however do not display any obvious signs of muscle pathol-
ogy at that time point. Hence, these mice were instead analyzed at
6 weeks of age correlating with clear signs of muscle pathology.
We observed a decreased expression of miR-1 and miR-133a
and an increase in miR-206 expression in dy3K/dy3K and dy2J/dy2J
quadriceps muscle compared with wild-type controls (Figure 1A).
Moreover, both miR-1 and miR-206 were differentially expressed
in dy3K/dy3K and dy2J/dy2J mice, which may reflect differences in
disease development. The observation that miR-206 expression
was significantly higher in muscle from dy3K/dy3K mice compared
with dy2J/dy2J, together with the established role of miR-206 in
muscle regeneration prompted us to investigate the number of
myofibers with central nuclei (reflecting overall muscle regener-
ation) and the number of fibers expressing embryonic myosin
heavy chain (eMHC, reflecting the initial phase of myofiber regen-
eration) in dy3K/dy3K and dy2J/dy2J mice (Yuasa et al., 2008;
Liu et al., 2012). We observed a significant increase in overall
myofiber regeneration in dy3K/dy3K compared with dy2J/dy2J mice,
closely resembling miR-206 expression (Figures 1A–C). How-
ever, staining against eMHC, which is transiently expressed in
nascent myofibers revealed a low number of positive fibers, both in
dy3K/dy3K and dy2J/dy2J mice, indicating that miR-206 expression
reflects the overall regenerative status of the muscle rather than
the initial stages of regeneration (Figures 1B,C). These findings
are consistent with the effect of induced muscle damage on miR-
206 expression, which increased markedly on day 5 post-injury
(Yuasa et al., 2008).
Taken together, miR-1 and miR-133a are significantly downreg-
ulated in dy3K/dy3K and dy2J/dy2J muscle while miR-206 expression
is upregulated, reflecting the overall regenerative status of the
dystrophic muscle.
EXPRESSION OF miR-21 IS DEREGULATED IN dy 3K /dy 3K AND dy 2J /dy 2J
QUADRICEPS MUSCLE
Dystrophic myofibers are progressively replaced by adipose and
fibrotic tissue leading to irreversible loss of muscle (Mann et al.,
2011). Laminin α2 chain-deficient muscles display extensive fibro-
sis, both in MDC1A patients and in dy3K/dy3K and dy2J/dy2J
mice as shown by Fast green and Sirius red staining (visualizing
non-collagenous and collagenous tissue, respectively) and bio-
chemical collagen quantification (Figure 2A). Newly published
data demonstrate a role of miR-21 and miR-29 as regulators of
fibrogenesis (Ardite et al., 2012; Wang et al., 2012).
Based on these observations we analyzed the expression of miR-
21 and miR-29c in muscle from dy3K/dy3K and dy2J/dy2J mice. We
noticed a significant upregulation of miR-21 in both dy3K/dy3K
and dy2J/dy2J mice compared with wild-type controls (Figure 2B).
However, we did not observe any significant difference in miR-29c
expression. Previous data suggest that miR-29c expression in dys-
trophic muscle depends on muscle group and age (Greco et al.,
2009; Roberts et al., 2012). It may be that the effect of laminin α2
chain-deficiency on miR-29c expression is influenced by similar
factors.
Dystrophic muscles are characterized by infiltration of inflam-
matory cells (Mann et al., 2011). This is also true for laminin
α2 chain-deficient muscle (Pegoraro et al., 1996). miR-223 has
been shown to be involved in granulocyte production and sev-
eral studies report increased expression of miR-223 in dys-
trophic muscle (Eisenberg et al., 2007; Johnnidis et al., 2008).
We did not observe any significant upregulation of miR-223
in quadriceps muscles from dy3K/dy3K or dy2J/dy2J mice at 3
and 6 weeks of age, respectively (Figure 2B). This is consistent
with the relatively low number of CD11b- and CD68-positive
immune cells (monocytes/macrophages) at the indicated time
points (Figure 2C).
CIRCULATING MUSCLE-SPECIFIC miRNAs ARE ENRICHED IN dy 3K /dy 3K
AND dy 2J /dy 2J MICE
In addition to aberrant miRNA expression in skeletal muscle, mus-
cular dystrophy patients and mice display altered levels of miRNAs
in the blood (Cacchiarelli et al., 2011; Mizuno et al., 2011; Vignier
et al., 2013). Hence, we investigated levels of muscle-specific miR-
1, miR-133a, and miR-206 in plasma from 3-week-old dy3K/dy3K
and 6-week-old dy2J/dy2J mice. We observed a significant increase
in miR-1 (~7-fold), miR-133a (~15-fold), and miR-206 (~15-
fold) compared with wild-type controls, however no significant
differences were observed between dy3K/dy3K and dy2J/dy2J mice
(Figure 3A).
Recent data suggest that extra-cellular miRNAs is the result of
selective rather than uncontrolled release from damaged myofibers
(Roberts et al., 2013). To investigate this further we analyzed
Frontiers in Aging Neuroscience www.frontiersin.org July 2014 | Volume 6 | Article 155 | 3
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Holmberg et al. Laminin-211 is required for correct miRNA expression
FIGURE 1 | Laminin α2 chain-deficiency results in altered expression of
muscle-specific miRNAs. (A) RT-qPCR analysis of indicated miRNAs in
muscles from 3-week-old dy3K/dy3K and 6-week-old dy2J/dy2J mice (n≥4).
(B) Transverse sections of muscles from WT, dy3K/dy3K, and dy2J/dy2J mice
stained for H&E to visualize histopathology and eMHC/Lamγ1 to identify early
regenerating fibers. Arrows indicate eMHC positive cells (green). Bar, 100µm.
(C) Percentage of fibers with centralized nuclei or positive for eMHC in
muscles from WT, dy3K/dy3K, and dy2J/dy2J mice (n≥3). WT, wild-type; H&E,
hematoxylin/eosin; eMHC, embryonic myosin heavy chain; Lamγ1, laminin γ1
chain. Error bars represent SEM, *P <0.05, **P < 0.01, ***P <0.001.
plasma creatine kinase (CK) levels, a classical index of sarcolem-
mal integrity. Significant increase in CK levels was observed only
in dy3K/dy3K mice (Figure 3B). Notably, the degree of sarcolemmal
damage between dy3K/dy3K and dy2J/dy2J mice is in sharp contrast
to levels of muscle-specific miRNAs in circulation, supporting the
observation that release of miRNAs into circulation is a regulated
process rather than simple leakage from damaged fibers. Taken
together, the abundance of circulating muscle-specific miRNAs is
significantly increased upon laminin α2 chain-deficiency.
Increased proteasomal activity is a feature of MDC1A and
recent studies demonstrated that proteasome inhibition partially
improves muscle integrity in dy3K/dy3K mice accompanied by
increased expression of miR-1 and miR-133a (Carmignac et al.,
2011; Körner et al., 2014). To determine if reduced muscle pathol-
ogy had an impact on plasma levels of dysregulated miRNAs,
dy3K/dy3K mice were given bortezomib (a proteasome inhibitor).
Notably, administration of bortezomib resulted in a partial nor-
malization of plasma levels of miR-1 and miR-133a in dy3K/dy3K
mice (Figure 3C). However, bortezomib did not affect miR-206
plasma levels. This is consistent with observations that bortezomib
does not significantly reduce myofiber regeneration in dy3K/dy3K
mice (Körner et al., 2014). In summary, the partial normalization
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FIGURE 2 | Fibrosis in laminin α2 chain-deficient muscle is associated
with increased expression of miR-21. (A) Left: transverse sections of
muscles from WT, dy3K/dy3K, and dy2J/dy2J mice stained for Fast green/Sirius
red to visualize non-collagenous and collagenous tissue, respectively. Bar,
100µm. Right: quantification of relative collagen content (fibrosis) in dy3K/dy3K
and dy2J/dy2J mice (n≥5). (B) RT-qPCR analysis of indicated miRNAs in
muscles from dy3K/dy3K and dy2J/dy2J mice (n≥4). (C) CD11b/CD68/Lamγ1
stained sections of muscles from WT, dy3K/dy3K, and dy2J/dy2J mice. Arrows
indicate CD11b and CD68-positive cells (green). Bar, 100µm. WT, wild-type;
Lamγ1, laminin γ1 chain. Error bars represent SEM, ***P <0.001.
of miR-1 and miR-133a in response to bortezomib administration
indicates that these miRNAs are promising disease biomarkers for
MDC1A.
miRNA EXPRESSION IN dy 3K /dy 3K MICE CHANGES DYNAMICALLY
OVER TIME
microRNA expression is a dynamic process possibly reflecting the
development of the underlying dystrophic pathology (Roberts
et al., 2013). Hence, we analyzed the expression of miRNAs in
dy3K/dy3K muscles and plasma at an early age (9 days of age). At
this time point, the number of regenerating fibers positive for
eMHC is high while the level of overall myofiber regeneration
is low, reflected in unaltered expression of miR-206 in muscle
(Figures 4A–C). In addition, at 9 days of age dy3K/dy3K mice
display extensive infiltration of inflammatory cells and accumu-
lation of extra-cellular matrix components (Figure 4A). Accord-
ingly, we noticed a significant increase in miR-223 (immune cells)
and miR-21 expression (fibrosis) in muscle from dy3K/dy3K mice
compared with wild-type controls (Figure 4C). Notably, expres-
sion of muscle-specific miR-1 and miR-133a were unaffected at
young ages (Figure 4C).
We also investigated levels of circulating muscle-specific miR-
NAs in young dy3K/dy3K mice. Extra-cellular levels of miR-1 and
miR-133a were unaltered whereas levels of miR-206 were signif-
icantly increased compared with wild-type controls (in contrast
to muscle) (Figures 4C,D). The discrepancy between muscle and
plasma levels of miR-206 could be due to plasma levels preceding
the increase in miR-206 expression in muscle. It is also possible that
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FIGURE 3 | Enrichment of muscle-specific miRNAs in plasma upon
laminin α2-deficiency. (A) RT-qPCR analysis of plasma levels of indicated
miRNAs in 3-week-old dy3K/dy3K and 6-week-old dy2J/dy2J mice (n≥4).
(B) Analysis of CK levels in plasma from WT, dy3K/dy3K, and dy2J/dy2J mice
(n≥4). (C) RT-qPCR analysis of plasma levels of indicated miRNAs in WT,
dy3K/dy3K, and bortezomib injected dy3K/dy3K mice (n≥4). WT, wild-type; CK,
creatine kinase. Error bars represent SEM, *P <0.05, **P <0.01,
***P <0.001.
additional muscle groups contribute to the increase in miR-206
plasma levels (Roberts et al., 2013). Taken together, abundance of
miRNAs in dy3K/dy3K mice is dynamic and changes as the muscular
dystrophy develops.
DISCUSSION
In the current study, we present evidences that MDC1A phys-
iopathology is associated with altered expression of miRNAs, both
in muscle and plasma. Specifically, we demonstrate that loss of
laminin α2 chain leads to downregulation of muscle-specific miR-
1 and miR-133a together with increased expression of miR-206 in
muscle, consistent with data on other types of muscular dystrophy.
The role of miR-206 in myofiber regeneration is well characterized
and loss of miR-206 leads to delayed regeneration upon induced
muscle damage (Liu et al., 2012). In contrast, the precise function
of miR-1 and miR-133a in skeletal muscle is less clear. Studies
on C2C12 myoblasts suggest that miR-133a and miR-1 promote
proliferation and differentiation, respectively (Chen et al., 2006).
However, mice deficient for miR-133a do not display any skeletal
muscle anomalies until they are adult and skeletal muscle from
miR-1-deficient mice is grossly normal (Zhao et al., 2007; Liu
et al., 2011). These observations make it difficult to draw any
firm conclusions regarding the impact of miR-133a and miR-1
dysregulation on the MDC1A pathology.
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FIGURE 4 | Dynamic miRNA expression in laminin α2-deficient
mice over time. (A) Transverse sections of muscles from 9-day-old WT
and dy3K/dy3K mice stained for eMHC/Lamγ1, H&E, Fast green/Sirius
red, and CD11b/CD68/Lamγ1. Arrows indicate CD11b and CD68-positive
cells (green). Bar, 100µm. (B) Percentage of fibers with centralized
nuclei or positive for eMHC in muscles from WT and dy3K/dy3K mice
(n≥3). (C) RT-qPCR analysis of indicated miRNAs in muscles from
9-day-old WT and dy3K/dy3K mice (n≥3). (D) RT-qPCR analysis of plasma
levels of indicated miRNAs in 9-day-old WT and dy3K/dy3K mice (n=4).
WT, wild-type; H&E, hematoxylin/eosin; eMHC, embryonic myosin
heavy chain; Lamγ1, laminin γ1 chain. Error bars represent SEM,
*P <0.05, **P <0.01.
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In this report, we also describe that miR-223 and miR-21
expression is positively associated with inflammation and fibro-
sis, respectively, in dy3K/dy3K and dy2J/dy2J muscle. Inflammation
in MDC1A muscles ultimately results in progressive and irre-
versible replacement of muscle by adipose and fibrotic tissue.
Severe inflammation in muscle from dy3K/dy3K mice is evident
already at 7 days of age (Gawlik et al., 2014). However, inflam-
mation appears arrested in older muscles (Figures 2C and 4A)
(Gawlik et al., 2014). Importantly, we show that miR-223 expres-
sion reflects the degree of immune cell infiltration in muscle from
dy3K/dy3K mice and could therefore be involved in modulating the
inflammatory response in MDC1A. The importance of immune
cells in chronic myopathic conditions is emphasized by exper-
iments on dystrophin-deficient mdx mice lacking functional B
and/or T lymphocytes. These mice displayed reduced levels of the
profibrotic cytokine transforming growth factor (TGF)-β and less
diaphragm fibrosis (Morrison et al., 2000; Farini et al., 2007).
Furthermore, muscle fibrosis is associated with disease progres-
sion in MDC1A. Despite efforts to combat fibrogenesis in laminin
α2-deficient mice, clinical applications for MDC1A remain years
away (Elbaz et al., 2012; Meinen et al., 2012). Hence, the recent
discovery that miR-21 and miR-29c can function as antifibrotic
molecules in dystrophic muscles suggests miRNAs as attractive
therapeutic candidates (Cacchiarelli et al., 2010; Ardite et al., 2012;
Wang et al.,2012). In contrast to miR-21,we did not observe altered
expression of miR-29c in dy3K/dy3K and dy2J/dy2J muscle. Expres-
sion of miR-29c is downregulated by TGF-β signaling, which is
increased in dystrophic skeletal muscle (Bernasconi et al., 1995,
1999). However, TGF-β signaling seems to be less pronounced
in MDC1A muscle, which may explain the unaltered expression
of miR-29c in dy3K/dy3K and dy2J/dy2J muscle (Bernasconi et al.,
1999). Collectively, these data suggest that fibrosis in MDC1A may
be driven by other molecules than TGF-β.
It should be noted that Roberts and colleagues demonstrated
important differences in miRNA expression between individual
muscle groups in the mdx mouse (Roberts et al., 2012). In this
report, miRNA expression analysis was limited to quadriceps mus-
cles. Future studies on miRNA expression in laminin α2-deficient
mice should include additional skeletal muscle groups.
Finally, we demonstrate that MDC1A is accompanied by
increased levels of circulating muscle-specific miRNAs, which are
partially normalized upon reduction of the dystrophic pathology.
The precise biological function for extra-cellular miRNA remains
largely unknown. However, we and others have demonstrated that
expression of muscle-specific miRNAs in muscle does not reflect
miRNA abundance in plasma or serum, indicating that miRNAs
could enter circulation by exocytosis or be released in vesicles
rather than by uncontrolled leakage. Moreover, the enrichment
of circulating muscle-specific miRNAs in laminin α2-deficient
mice is similar to observations in the mdx mouse, despite sig-
nificantly more sarcolemmal damage in the latter (Straub et al.,
1997; Roberts et al., 2012).
We also demonstrate that levels of plasma miRNAs in dy3K/dy3K
change over time. These observations are consistent with data from
other muscle disorders and suggest that levels of circulating miR-
NAs could serve as biomarkers for monitoring treatment strategies
and diagnosis of MDC1A. Current methods are largely based on
muscle biopsies and CK assays. In contrast to CK, extra-cellular
miRNAs are resistant to stress and more accurately reflects disease
severity (Cacchiarelli et al., 2011; Mizuno et al., 2011). In addition,
miRNAs are present in numerous biological fluids easily accessi-
ble for analysis, including saliva and urine (De Guire et al., 2013).
However, we observed a significant variability in levels of muscle-
specific miRNAs in plasma from dy3K/dy3K and dy2J/dy2J mice,
similar to studies on mdx mice (Cacchiarelli et al., 2011; Roberts
et al., 2012).
A possible reason is that dystrophic muscles typically enter
cycles of myofiber degeneration/regeneration, which lead to irre-
versible muscle wasting over time. Variation in onset of these
regeneration cycles between mice could at least explain the vari-
ability in miR-206 levels in circulation. To establish miRNAs as
biomarkers in MDC1A pathology, additional studies identifying
and coupling miRNA levels in biofluids to pathology markers
need to be performed. Moreover, global analysis of extra-cellular
miRNA levels in laminin α2-deficient animals should facilitate the
identification of miRNA profiles that correlate well with degree of
muscle pathology.
Taken together, the discovery that miRNA expression is altered
in MDC1A mouse models opens new strategies to combat this dev-
astating disorder. Despite several challenges, recent refinements in
delivery carriers, miRNA mimic molecules, and anti-miRs have
improved delivery, specificity, and stability of miRNA therapeu-
tics. Currently, one miRNA drug (miravirsen) has reached clinical
trials and additional miRNA drugs are likely to enter clinical trials
soon (Gebert et al., 2014).
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